133 completed, 32 terminated, 25 unknown, 22 recruiting. 240 Phase 3, 39 Phase 2.
Follow Colitis: new trials by email Literature Review of Colitis trials Research Report on Colitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative Colitis Nitazoxanide (NTZ) - Ulcerative Colitis (UC) | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 44 | 2027-01-01 | 2026-09-15 |
| Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis Ponesimod, Placebo - Ulcerative Colitis (UC) | Phase 3 | Recruiting | Vanda Pharmaceuticals | 150 | 2026-09-01 | 2026-08-18 |
| Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer Vedolizumab, Placebo - IrAE, Immune-related Adverse Event | Phase 2 / Phase 3 | Recruiting | AHS Cancer Control Alberta | 36 | 2026-08-13 | 2026-08-27 |
| Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial) Modafinil, Placebo - Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Chronic Fatigue | Phase 2 / Phase 3 | Recruiting | Radboud University Medical Center | 60 | 2026-08-03 | 2026-09-14 |
| Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis Hemay005 tablet, Placebo - Ulcerative Colitis (UC) | Phase 3 | Not yet recruiting | Ganzhou Hemay Pharmaceutical Co., Ltd | 360 | 2026-06-01 | 2026-06-16 |
| A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis JNJ-78934804, Guselkumab - Colitis, Ulcerative | Phase 3 | Recruiting | Janssen Research & Development, LLC | 644 | 2026-05-23 | 2026-10-13 |
| A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis Duvakitug, Placebo - Ulcerative Colitis | Phase 3 | Recruiting | Sanofi | 751 | 2026-01-16 | 2026-10-16 |
| A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) Vedolizumab SC, No Intervention - Ulcerative Colitis, Crohn's Disease | Phase 3 | Recruiting | Takeda | 70 | 2025-10-27 | 2026-10-09 |
| Risankizumab for Fibrostenotic Crohn's Disease Treatment Ustekinumab, Risankizumab - Crohn Disease, Crohn Disease and Ulcerative Colitis | Phase 3 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 260 | 2025-10-20 | 2025-09-16 |
| An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis Duvakitug, Placebo - Ulcerative Colitis | Phase 3 | Recruiting | Sanofi | 980 | 2025-10-08 | 2026-10-23 |
| A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis Icotrokinra, Placebo - Colitis, Ulcerative | Phase 3 | Recruiting | Janssen Research & Development, LLC | 882 | 2025-10-01 | 2026-09-25 |
| A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis Filgotinib - Ulcerative Colitis | Phase 3 | Recruiting | Alfasigma S.p.A. | 80 | 2025-09-29 | 2026-10-20 |
| A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis Mesalamine, Placebo - Ulcerative Colitis (UC) | Phase 3 | Withdrawn | AbbVie | 2025-09-15 | 2025-08-12 | |
| A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis Risankizumab - Ulcerative Colitis | Phase 3 | Recruiting | AbbVie | 120 | 2025-07-28 | 2026-10-27 |
| Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis Probiotics 6600, Placebo - Colitis, IBD (Inflammatory Bowel Disease) | Phase 2 / Phase 3 | Recruiting | Changhai Hospital | 120 | 2025-07-01 | 2025-07-02 |
| Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study Mirikizumab, Tirzepatide, Placebo - Ulcerative Colitis, Obesity or Overweight | Phase 3 | Recruiting | Eli Lilly and Company | 350 | 2025-06-26 | 2026-10-07 |
| A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab Risankizumab, Vedolizumab - Ulcerative Colitis | Phase 3 | Active not recruiting | AbbVie | 573 | 2025-06-17 | 2026-08-04 |
| Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis Upadacitinib Oral Product - Colitis, Ulcerative | Phase 3 | Recruiting | McMaster University | 134 | 2025-04-16 | 2025-06-22 |
| A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Vedolizumab IV, Vedolizumab SC - Ulcerative Colitis, Crohn's Disease | Phase 3 | Recruiting | Takeda | 70 | 2025-01-22 | 2026-08-03 |
| Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) Tulisokibart, Placebo to tulisokibart - Crohn Disease, Colitis, Ulcerative | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1380 | 2024-11-25 | 2026-10-30 |
Showing 20 of 240. Sign in to see all of them.
Colitis, Ulcerative (223) · Inflammatory Bowel Diseases (47) · Crohn Disease (31) · Gastrointestinal Diseases (8) · Ulcer (8) · Colonic Diseases (6) · Colitis, Collagenous (5) · Diarrhea (5) · Digestive System Diseases (5) · Gastroenteritis (5) · Intestinal Diseases (5) · Anemia (4) · Anemia, Iron-Deficiency (4) · Colitis, Microscopic (4)
Digestive System Diseases (235) · Gastroenteritis (235) · Intestinal Diseases (235) · Colonic Diseases (234) · Gastrointestinal Diseases (232) · Inflammatory Bowel Diseases (182) · Pathological Conditions, Signs and Symptoms (24) · Pathologic Processes (11) · Signs and Symptoms (8) · Hemic and Lymphatic Diseases (6) · Signs and Symptoms, Digestive (6) · Behavior (5) · Colitis, Microscopic (5) · Disease Attributes (5)
Mesalamine (39) · vedolizumab (16) · Adalimumab (13) · Budesonide (13) · Infliximab (11) · mirikizumab (8) · Fecal Microbiota Transplantation (7) · etrolizumab (6) · golimumab (5) · ozanimod (5) · risankizumab (5) · tofacitinib (5) · GLPG0634 (4) · Prednisolone (4) · Ustekinumab (4)
Janssen Research & Development, LLC (16) · Bausch Health Americas, Inc. (14) · AbbVie (12) · Takeda (10) · Shire (9) · Dr. Falk Pharma GmbH (8) · Eli Lilly and Company (8) · Ferring Pharmaceuticals (7) · Pfizer (7) · Hoffmann-La Roche (6) · Warner Chilcott (6) · Facet Biotech (4) · Merck Sharp & Dohme LLC (4) · AbbVie (prior sponsor, Abbott) (3) · Abivax S.A. (3)
United States (135) · Poland (95) · Germany (90) · Canada (89) · Belgium (83) · Hungary (76) · France (74) · Israel (73) · United Kingdom (73) · Italy (71) · Czechia (68) · Japan (66) · Netherlands (64) · Spain (64) · Australia (63)
Bruce Sands, MD, PhD (3) · Severine Vermeire, MD, PhD (3)
PMID 32445184, PMID 29850873, PMID 30476584, PMID 31077827, PMID 31599001, PMID 32766762, PMID 32816215, PMID 32870265, PMID 32964215, PMID 33324993, PMID 33684552, PMID 34614208, PMID 35648151, PMID 35792493, PMID 36124702, PMID 36336750, PMID 36342120, PMID 36526796, PMID 36931693, PMID 37402275, PMID 37560161, PMID 38310565, PMID 38425446, PMID 40013523, PMID 26563167, PMID 27959607, PMID 28467869, PMID 29028981, PMID 29142515, PMID 29380251, PMID 29409871, PMID 29743836, PMID 29909019, PMID 30739254, PMID 31279870, PMID 31982148, PMID 33127596, PMID 33513294, PMID 34035832, PMID 34077627, PMID 34165201, PMID 35380664, PMID 35380740, PMID 35934286, PMID 36150926, PMID 36271912, PMID 36506749, PMID 37368103, PMID 37391056, PMID 38778549
2023 (16), 2017 (10), 2015 (8), 2016 (6), 2018 (6), 2004 (5), 2019 (4), 2008 (3), 2025 (3), 2014 (2), 2009 (1), R01HD099344 (1), UL1RR024150 (1)